Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

Inclusion Criteria:

- Male or female ≥18 and ≤80 years of age at time of screening

- Diagnosed with rheumatoid arthritis as determined by meeting 1987 American College of
Rheumatology (ACR) classification criteria and has had rheumatoid arthritis for at
least 6 months

- Moderate rheumatoid arthritis during screening, as defined by a disease activity
score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) > 3.2
and ≤ 5.1

- Active rheumatoid arthritis defined as ≥ 3 swollen joints (out of 28 joints examined)
and ≥ 3 tender/painful joints (out of 28 joints examined) at screening and baseline.
(A full 66/68 count joint count will be performed at baseline, but only joints in the
28-count joint count will be considered for eligibility. The 28-joint count consists
of the finger joints excluding the distal interphalangeal joints, the wrists, elbows,
shoulders, and knees)

- Must be currently taking a DMARD such as methotrexate, sulfasalazine, leflunomide,
minocycline, and/or hydroxychloroquine

Exclusion Criteria:

- Prosthetic joint infection within 5 years of screening or native joint infection
within 1 year of screening

- Class IV rheumatoid arthritis according to ACR revised response criteria

- Any active infection (including chronic or localized infections) for which
anti-infectives were indicated within 28 days prior to first investigational product
dose

- Previously used more than one experimental biologic DMARD. Patient with prior use of
no more than one experimental biologic is permitted if the subject received no more
than 8 weeks of treatment. The use of the experimental biologic must not have
occurred within 2 months of the first dose of investigational product

- Previously used more than one commercially available biologic DMARD. Subject with
prior use of no more than one commercially available biologic is permitted if the
patient received no more than 8 weeks of treatment and did not discontinue because of
lack of effect. The use of the biologic must not have occurred within 2 months of the
first dose of investigational product. Acceptable prior use of biologics include the
following examples:

- No more than 4 injections of adalimumab

- No more than 8 (50 mg) injections of etanercept

- No more than 2 infusions of infliximab

- No more than 2 infusions of abatacept

- Additional inclusion (exclusion) criteria may apply